The BioSTAR® device versus the CardioSEAL® device in patent foramen ovale closure: Comparison of mid-term efficacy and safety

Ben J. Van Den Branden, Justin G. Luermans, Martijn C. Post, Herbert W. Plokker, Jurriën M. Ten Berg, Maarten J. Suttorp

Research output: Contribution to journalArticleAcademicpeer-review

11 Citations (Scopus)

Abstract

Aims: To compare the mid-term efficacy and safety of the bioabsorbable BioSTAR® device with the nonbioabsorbable CardioSEAL® device for percutaneous patent foramen ovale (PFO) closure. Methods and results: All 81 consecutive patients who underwent PFO closure with the CardioSEAL® or BioSTAR® device between June 2003 and July 2008 were included. The presence of a residual shunt (minimal, moderate or large) was measured in both groups at six months follow-up, using contrast transthoracic echocardiography. Forty-four patients (48.4±11.4 years) received the CardioSEAL® device and 37 patients the BioSTAR® device (47.9±10.7 years). There were no significant differences in short-term complications. Two patients who received the BioSTAR® device developed a recurrent transient cerebral ischaemic event. Overall, atrial arrhythmias occurred in 19%, with no difference between both groups. At six months, a residual shunt was present in 29% (27% minimal, 2% moderate) using the CardioSEAL® device compared to 28% (17% minimal, 11% moderate) using the BioSTAR® device (p=0.18). A predictor for residual shunt could not be found. Conclusions: There is no difference in safety and efficacy at six months between the CardioSEAL® and BioSTAR® device used for PFO closure. However, using the BioSTAR® device tends to be associated with a higher percentage of moderate shunting.

Original languageEnglish
Pages (from-to)498-504
Number of pages7
JournalEuroIntervention
Volume6
Issue number4
DOIs
Publication statusPublished - 1 Jan 2010

Keywords

  • Patent foramen ovale
  • Residual shunt
  • Transcatheter closure

Fingerprint

Dive into the research topics of 'The BioSTAR® device versus the CardioSEAL® device in patent foramen ovale closure: Comparison of mid-term efficacy and safety'. Together they form a unique fingerprint.

Cite this